Last reviewed · How we verify

NCT06005155

Lithium Versus Anticonvulsants and the Risk of Physical Disorders

Completed Last updated 22 August 2023
What this trial tests

trial testing Lithium in Bipolar Disorder in 169,285 participants. Completed in 1 July 2023.

Timeline
1 June 2022
Primary endpoint
1 July 2023
1 July 2023

Quick facts

Lead sponsorMental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment169,285
Start date1 June 2022
Primary completion1 July 2023
Estimated completion1 July 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Who can join

Adults 5 to 100, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nationwide population-based register linkage study covering the entire 5.9 million inhabitants in Denmark systematically investigating the associations between sustained long-term use of lithium versus lamotrigine and valproate, and the risk of a range of physical disorders emulating a randomized trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lithium

Trials testing the same drug.

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

Other Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06005155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing